Total Valuation
HLB Life Science Co.,Ltd. has a market cap or net worth of ₩304.62B. The enterprise value is ―.
Market Cap₩304.62B
Enterprise Value―
Share Statistics
HLB Life Science Co.,Ltd. has 121,917,060 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding121,917,060
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
HLB Life Science Co.,Ltd.’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -4.51%.
Return on Equity (ROE)-0.34
Return on Assets (ROA)-0.21
Return on Invested Capital (ROIC)-4.51%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee10.00T>
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.10
Inventory Turnover6.81
Valuation Ratios
The current PE Ratio of HLB Life Science Co.,Ltd. is ―. HLB Life Science Co.,Ltd.’s PEG ratio is 0.00895.
PE Ratio―
PS Ratio30.16
PB Ratio4.64
Price to Fair Value4.64
Price to FCF-28.24
Price to Operating Cash Flow-14.08
PEG Ratio0.00895
Income Statement
In the last 12 months, HLB Life Science Co.,Ltd. had revenue of 45.75B and earned -99.79B in profits. Earnings per share was -818.56.
Revenue45.75B
Gross Profit-494.41M
Operating Income-21.02B
Pretax Income-100.57B
Net Income-99.79B
EBITDA-83.58B
Earnings Per Share (EPS)-818.56
Cash Flow
In the last 12 months, operating cash flow was -22.93B and capital expenditures -25.94B, giving a free cash flow of -48.88B billion.
Operating Cash Flow-22.93B
Free Cash Flow-48.88B
Free Cash Flow per Share-400.89
Dividends & Yields
HLB Life Science Co.,Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.34
52-Week Price Change-32.96%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)503.97K
Important Dates
HLB Life Science Co.,Ltd. upcoming earnings date is Aug 7, 2026, TBA (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 7, 2026
Ex-Dividend Date―
Financial Position
HLB Life Science Co.,Ltd. as a current ratio of 0.58, with Debt / Equity ratio of 55.88%
Current Ratio0.58
Quick Ratio0.52
Debt to Market Cap0.11
Net Debt to EBITDA-1.76
Interest Coverage Ratio-1.79
Taxes
In the past 12 months, HLB Life Science Co.,Ltd. has paid -666.74M in taxes.
Income Tax-666.74M
Effective Tax Rate<0.01
Enterprise Valuation
HLB Life Science Co.,Ltd. EV to EBITDA ratio is -18.27, with an EV/FCF ratio of -31.25.
EV to Sales33.38
EV to EBITDA-18.27
EV to Free Cash Flow-31.25
EV to Operating Cash Flow-66.59
Balance Sheet
HLB Life Science Co.,Ltd. has ₩13.88B in cash and marketable securities with ₩160.36B in debt, giving a net cash position of -₩146.48B billion.
Cash & Marketable Securities₩13.88B
Total Debt₩160.36B
Net Cash-₩146.48B
Net Cash Per Share-₩1.20K
Tangible Book Value Per Share₩2.02K
Margins
Gross margin is -4.44%, with operating margin of -45.95%, and net profit margin of -218.12%.
Gross Margin-4.44%
Operating Margin-45.95%
Pretax Margin-219.81%
Net Profit Margin-218.12%
EBITDA Margin-182.67%
EBIT Margin-194.14%
Analyst Forecast
The average price target for HLB Life Science Co.,Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-51.32%
EPS Growth Forecast75.53%